Thus, ERCC1 inhibitor combined with either traditional regimens (i.e., chemotherapy or radiotherapy) or lately immunotherapies (i.e., anti-PD1, anti-CTLA4, or both) may obtain promising antitumor efficacy on cervical cancer. This evidence concerns the gene ERCC1 and cervical cancer.